SLC5A2 and cancer: Additionally, SGLT2 inhibitors may attenuate cancer therapy-related cardiac dysfunction (CTRCD), a common complication of anthracyclines and targeted therapies, by preserving myocardial energetics and reducing fibrosis [15,16].